Last reviewed · How we verify

brimonidine tartrate ophthalmic solution — Competitive Intelligence Brief

brimonidine tartrate ophthalmic solution (brimonidine tartrate ophthalmic solution) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Alpha-2 adrenergic receptor agonist. Area: Ophthalmology.

marketed Alpha-2 adrenergic receptor agonist Alpha-2 adrenergic receptor Ophthalmology Small molecule Live · refreshed every 30 min

Target snapshot

brimonidine tartrate ophthalmic solution (brimonidine tartrate ophthalmic solution) — Allergan. Brimonidine tartrate is an alpha-2 adrenergic receptor agonist that reduces intraocular pressure by decreasing aqueous humor production and increasing uveoscleral outflow.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
brimonidine tartrate ophthalmic solution TARGET brimonidine tartrate ophthalmic solution Allergan marketed Alpha-2 adrenergic receptor agonist Alpha-2 adrenergic receptor
Group D : Dexmedetomidine + propofol group Group D : Dexmedetomidine + propofol group Seoul National University Hospital marketed Sedative-hypnotic combination (alpha-2 agonist + GABA-A agonist) Alpha-2 adrenergic receptor (dexmedetomidine); GABA-A receptor (propofol)
Escitalopram+Mirtazapine Escitalopram+Mirtazapine Ministry of Health & Welfare, Korea marketed Antidepressant combination (SSRI + NaSSA) Serotonin transporter (SERT), norepinephrine transporter (NET), alpha-2 adrenergic receptors, histamine H1 receptors
Methadone-dexmedetomidine-ketamine combination Methadone-dexmedetomidine-ketamine combination University of Missouri-Columbia marketed Anesthetic combination (opioid + alpha-2 agonist + NMDA antagonist) Mu opioid receptor, alpha-2 adrenergic receptor, NMDA receptor
Dexmedetomidine (DEX) Dexmedetomidine (DEX) Ain Shams University marketed Alpha-2 adrenergic receptor agonist Alpha-2 adrenergic receptor
Normal saline, Lidocaine, dexmetomidine Normal saline, Lidocaine, dexmetomidine Kasr El Aini Hospital marketed Local anesthetic combination with sedative-analgesic agent Voltage-gated sodium channels (lidocaine); alpha-2 adrenergic receptors (dexmedetomidine)
Norepinephrine (Levophed) Norepinephrine (Levophed) University of Louisville marketed Catecholamine; sympathomimetic amine Alpha-1 adrenergic receptor; alpha-2 adrenergic receptor; beta-1 adrenergic receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Alpha-2 adrenergic receptor agonist class)

  1. Allergan · 3 drugs in this class
  2. Eye & ENT Hospital of Fudan University · 2 drugs in this class
  3. National Cancer Institute, Egypt · 2 drugs in this class
  4. The University of Hong Kong · 2 drugs in this class
  5. Sindh Institute of Urology and Transplantation · 2 drugs in this class
  6. Fayoum University Hospital · 1 drug in this class
  7. First Affiliated Hospital of Chongqing Medical University · 1 drug in this class
  8. Guangzhou General Hospital of Guangzhou Military Command · 1 drug in this class
  9. Icahn School of Medicine at Mount Sinai · 1 drug in this class
  10. KAT General Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). brimonidine tartrate ophthalmic solution — Competitive Intelligence Brief. https://druglandscape.com/ci/brimonidine-tartrate-ophthalmic-solution. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: